Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026
Beam Therapeutics Inc BEAM
$25.52
▼ -3.66%
($-0.97)
🔥 High Short Interest
🎢 High Beta
📅 Earnings This Week
Open
$26.83
Prev Close
$26.49
Day Range
$25.36 – $26.93
52W Range
$15.60 – $38.26
Market Cap
$2.63B
Beta
2.22
EPS (TTM)
$-0.64
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-02-06 |
| Shares Out. | 102,880,000 |
| Website | beamtx.com/ ↗ |
| Phone | 13026587581 |
| Employees | 522 |
| Revenue | $31.7M |
| Gross Profit | $31.7M |
| Net Income | -$94.3M |
| Free Cash Flow | -$383.8M |
| Total Assets | $1.48B |
| Total Liabilities | $316.4M |
| Equity | $1.16B |
About Beam Therapeutics Inc
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Beam Therapeutics Inc is a publicly traded company under the ticker symbol BEAM on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
25 analysts (2026-07-01)